Rhodanine derivative, process for preparing the same and pharmaceutical composition containing the same
申请人:Kaken Pharmaceutical Co., Ltd.
公开号:EP0143461A2
公开(公告)日:1985-06-05
A rhodanine derivative having the following general formula (I):
wherein R is an acyclic alkyl group having 2 to 10 carbon atoms which may be substituted by a halogen atom; an acyclic alkenyl group having 2 to 19 carbon atoms which may be substituted by a halogen atom; a mono- or di-alkylamino group having 1 to 6 carbon atoms which may be substituted by a hydroxyl group; an alkenylamino group having 3 to 6 carbon atoms; a phenylamino group, the benzene ring of which may be substituted by a lower alkyl group, a lower alkoxyl group, phenyl group or a halogen atom; or a cyclic amino group which may contain in the ring an oxygen atom or a nitrogen atom to which a lower alkyl group is attached; or a nontoxic salt thereof. The rhodanine derivative has potent platelet aggregation inhibiting activity and aldose reductase inhibiting activity and therefore is useful as a therapeutic agent for diabetic complications.
具有以下通式(I)的罗丹宁衍生物:
其中 R 是具有 2 至 10 个碳原子、可被卤素原子取代的无环烷基;具有 2 至 19 个碳原子、可被卤素原子取代的无环烯基;具有 1 至 6 个碳原子、可被羟基取代的单烷基或二烷基氨基;具有 3 至 6 个碳原子的烯胺基;苯胺基,其苯环可被低级烷基、低级烷氧基、苯基或卤素原子取代;或环状氨基,其环中可含有一个氧原子或一个氮原子,并与低级烷基相连;或其无毒盐。罗丹宁衍生物具有强效的血小板聚集抑制活性和醛糖还原酶抑制活性,因此可用作糖尿病并发症的治疗剂。